Document is current
Any future updates will be listed below
-
Authors
Chakraborty, Soura
Pramanik, Jhuma
Alviter-Raymundo, Gustavo
Ward, Christopher J.
Shaji, Sanu K.
Yamashita-Kanemaru, Yumi https://orcid.org/0000-0002-2475-8858
Ali, Fatma Abo Zakaib
Banik, Debasis
Zhang, Ziwei
Veiga-Villauriz, Clara
Homer, Natalie Z. M.
Simpson, Joanna
Laforest, Sofia
Tong, Shanlin
Zhao, Qiuchen
Roy, James https://orcid.org/0000-0001-9178-8953
Iqbal, Muhammad
Morris, Andrew Conway
Chapman, Michael A.
Roychoudhuri, Rahul
Hussein, Hosni
Klenerman, David
Saeb-Parsy, Kourosh
Mahata, Bidesh https://orcid.org/0000-0002-4506-0184
-
Funding
Funding for this research was provided by:
Cancer Research UK (RCCFEL\100095))
RCUK | Medical Research Council (MR/V028995/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/V006126/1)
- License Information
-
More Information
Article History
Received: 28 December 2024
Revised: 16 January 2026
Accepted: 5 February 2026
First Online: 9 April 2026
Competing interests
: B.M. and S.C. are inventors on a patent application (under processing, to be filed by the University of Cambridge) related to the application of cortisol-resistant CEACAM5-CAR-NK therapy in steroidogenic lung cancer. A.C.M. reports speaking fees from Biomerieux, Thermo-Fisher, Fischer and Paykel, and Boston Scientific. He sits on the scientific advisory board of Cambridge Infection Diagnostics. The remaining authors declare no competing interests.
